Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,569 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastrointestinal Tract Clear all

Conditions: Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: Recombinant Interleukin-12; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: TU2218 + KEYTRUDA® (Pembrolizumab); Drug
Lead sponsor: TiumBio Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: San Antonio, Texas • Tyler, Texas • Spokane, Washington

Conditions: Urinary Tract Infection
Interventions: Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1), Placebo; Dietary Supplement · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 17 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Cystic Fibrosis
Interventions: Linezolid; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prediabetes, Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Interventions: CGM Dynamic Index (CDI); Device
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Primary Biliary Cirrhosis
Interventions: Clinic visit, Baseline visit; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Primary Biliary Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Cystic Fibrosis
Interventions: Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF), Supportive Psychotherapy (Treatment as Usual Control); Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions: 1.0% IP-001 for Injection; Drug
Lead sponsor: Immunophotonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma

Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions: ONM-100; Drug
Lead sponsor: OncoNano Medicine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas

Conditions: Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: AVA6103; Drug
Lead sponsor: Avacta Life Sciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more

Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions: ESG + lifestyle modification, Lifestyle modification; Device · Behavioral
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Morgantown, West Virginia

Conditions: Therapeutic Endoscopic Ultrasound, Advanced Endoscopy, Therapeutic Endoscopy, Interventional Endoscopy, Interventional Endoscopic Ultrasound, Gastro-Intestinal Disorder, Gastrointestinal Disease, Gastrointestinal Cancer, Gastrointestinal Dysfunction, Gastrointestinal Fistula, Gastrointestinal Infection, Gastrointestinal Injury, Pancreatic Disease, Bile Duct Diseases
Interventions: Therapeutic Endoscopic Ultrasound; Procedure
Lead sponsor: Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Inflammation
Interventions: Western style diet (high fat and low in calcium), Prudent-style diet (low fat and high in calcium); Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 50 Years to 72 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Immune Checkpoint Inhibitors, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Gastrointestinal Cancer, Squamous Cell Carcinoma
Interventions: Immunotherapy; Biological
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Tucson, Arizona • Albuquerque, New Mexico • Oklahoma City, Oklahoma + 3 more

Conditions: Cystic Fibrosis, Diabetes Mellitus
Interventions: Stable isotopes; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Plasma Cell Disorders
Interventions: Non-interventional study (observational); Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dysphagia, Dysphonia
Interventions: Voice and Swallowing evaluations; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Apparent Life Threatening Event, Gastroesophageal Reflux, Aspiration
Interventions: Rice cereal, Enfamil AR; Dietary Supplement
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Years to 1 Year
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Interventions: DSP107, Atezolizumab; Biological
Lead sponsor: Kahr Medical; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more

Conditions: Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions: MORAb-066; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions: TC-510, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: TCR2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Not listed
Lead sponsor: Biocerna LLC; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fulton, Maryland

Search by objective public record fields.

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Probiotics in Girls With Spina Bifida

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Acceptance and Commitment Therapy vs. Supportive Psychotherapy With Cystic Fibrosis Patients

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Effects of a Western-type Diet on Colorectal Inflammation

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery

A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency